Hemostemix

About:

Hemostemix is a public clinical-stage biotechnology company.

Website: http://www.hemostemix.com/

Twitter/X: hemostemix

Top Investors: MUHC Foundation, Wood Capital

Description:

Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It develops cell therapy products from the patient’s own blood, a relatively non-invasive source of therapeutic cells. The company’s lead product is ACP-01, which is in Phase II clinical trial for the treatment of critical limb ischemia. It is also developing various types of cells products, such as bone cell precursors, myocardial cell precursors, and neural cell precursors.